Table 2

The efficacy of triplet and doublet combinations in patients with high-risk cytogenetics.

	Regimen	High risk cytogenetics (%)	Median PFS (HR, P)

			All high-risk	del(17p)	t(4;14)
POLLUX [58]	DRd vs. Rd	15.4% vs. 16.6%	22.6 vs. 10.2 mo (HR, 0.53 P=0.921)	N/A	NA
ASPIRE [21]	KRd vs. Rd	12.1% vs. 13.1%	23.1 vs. 13.9 mo (HR, 0.70 P=0.0829)	24.5 vs. 11.1 mo (HR, N/A)	23.1 vs. 16.7 mo (HR, N/A)
ELOQUENT-2 [22, 62]	ERd vs. Rd	N/A	N/A	21.2 vs. 14.9 mo (HR, 0.65)	15.8 vs. 5.5 mo (HR, 0.53)
TOURMALINE MM-1 [19]	IRd vs. Rd	21% vs. 17%	21.4 vs. 9.7 mo (HR, 0.543 P=0.021)	21.4 vs. 9.7 (HR, 0.596)	18.5 vs. 12 mo (HR, 0.645)
CASTOR [20, 59]	DVd vs. Vd	22.7% vs. 21.3%	11.2 vs. 7.2 mo (HR, 0.45 P=0.0053)	N/A	NA
ENDEAVOR [18]	Kd vs. Vd	21% vs. 24%	8.8 vs. 6.0 mo (HR, 0.646 P=0.025)	7.6 vs. 4.9 mo(HR, N/A P=0.13)	10.1 vs. 6.8 mo (HR, N/A P=0.03)

Abbreviations: DRd, daratumumab-Rd; DVd, daratumumab-Vd; ERd, elotuzumab-Rd; HR, hazard ratio; IRd, ixazomib-Rd; Kd, carfilzomib-dexamethasone; KRd, carfilzomib-Rd; N/A, not available; OS, overall survival; PFS, progression-free survival; Rd, lenalidomide-low-dose dexamethasone; Vd, bortezomib-dexamethasone.

Blood Res 2020;55:S43~S53 https://doi.org/10.5045/br.2020.S008